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Gareth Evans et al. in a recent article in the journal [http://
www.ncbi.nlm.nih.gov/pubmed/24687378] concluded that
survival from breast cancer in very high risk women is
better in screened versus unscreened women with or
without a demonstrated genetic cause, and that BRCA2
mutation carriers may benefit from MRI screening in
addition to mammography (Mx). However, this may not be
the case for BRCA1 mutation carriers. Their dataset
included no more than 27 and 24 BRCA1 breast cancer
cases detected through Mx or MRI, respectively. We
recently reported survival in BRCA1 mutation carriers
diagnosed with breast cancer through annual Mx and MRI
[http://www.ncbi.nlm.nih.gov/pubmed/23615785]. The main
finding was that despite detecting tumours at an early stage,
survival was inferior to what might have been expected
according to Kurian et al. [http://www.ncbi.nlm.nih.gov/
pubmed/22231042]. Referring to our results, Evans et al.
state in their discussion that ‘.. formal evidence for a sur-
vival advantage (for MRI versus mammography alone) has
not so far been published’.
In order to make our data for patients followed at the
outpatient clinic at Oslo University Hospital available to
all, we here present updated survival analysis in the MRI
series previously reported (MRI series), and compare that
series to survival in BRCA1 breast cancer cases detected
through annual screening with mammography without MRI
(Mx series).
Our selection, methods and ethics were described in our
recent publication mentioned above. The Mx series were
the prospectively detected breast cancer cases before MRI
was added to the protocol for BRCA1 mutation carriers in
2001, and those subjected to annual Mx alone based on
family history before their BRCA1 mutations were detected
subsequently. In contrast to our previous report, only
patients not having had any cancer before or at first planned
examination were included in the present analysis.
We diagnosed 6 carcinoma in situ in the Mx series and 3
in the MRI series.
Kaplan–Meier survival analyses were performed in the
47 invasive cancer cases detected in the Mx series among
whom 12 had died, and in the 45 invasive cancer cases in
the MRI series among whom 8 had died. None of the
deceased had any other cancers. 5- and 10-years survival
was 0.81 (95 % CI 0.63–0.88) and 0.72 (95 % CI
0.60–0.86), respectively, in the Mx series, compared to
0.82 (95 % CI 0.63–0.92) and 0.73 (95 % CI 0.52–0.86) in
the MRI series (Fig. 1).
Age (grouped as \50 years/[ = 50 years), tumour size
(\=10 mm/11–20 mm/[ 20 mm), nodal spread (yes/no),
ER, PR and grade were compared with survival through Cox
proportional hazard models in the combined series. None
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gave significant results for univariate analyses (p C 0.18 for
any), nor for multivariate analyses (p C 0.24).
The findings in this larger series than the one reported by
Gareth Evans et al. support their notion that there may be
no additional survival benefit from early diagnosis through
MRI compared to Mx for BRCA1 mutation carriers: As
previously reported, tumours did appear to be downstaged
in the MRI series compared to the Mx series—but the
expected improved survival was not observed, and there
was no association with survival and stage at diagnosis,
which would have been expected if the earlier stage at
diagnosis in the MRI series were to be associated with
better prognosis. Prevalence of carcinoma in situ was low
in both series. Time-trends in treatment are potential con-
founders to survival studies recruiting patients over many
years: The MRI cases were treated in more recent years
than the Mx cases and would have been expected to have
improved survival because of that, nonetheless this was not
found. We had expected a right-shift in the survival curve
for the MRI series reflecting the earlier diagnosis even in
the absence of a ‘true’ improved survival; however, this
was not found. Our population has specific founder BRCA1
mutations, and the female carriers may be subjected to
different environment factors compared to carriers in other
populations.
We had no control group without screening, and our
results are not in conflict with the conclusion by Gareth
Evans et al. that early diagnosis and treatment may be
associated with improved survival. Our results address the
putative benefit of adding MRI to annual Mx, for which
none was apparent.
We look forward to reports from other groups on the
observed survival related to early diagnosis with MRI in
BRCA1 mutation carriers, because despite our series being
the largest reported so far, we are still short of patients
included to be sure that results are not caused by chance
variation based on limited numbers.
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Fig. 1 Survival in the MRI and Mx series with 95 % CIs
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